Merck KGaA Invests in Biopharmaceuticals Fill-Finish Site - - BioPharm International

ADVERTISEMENT

Merck KGaA Invests in Biopharmaceuticals Fill-Finish Site


Merck KGaA plans to invest €50 million (68 million USD) in its Italian production site in Bari to respond to the rising demand for biopharmaceuticals, the company announced in a press release. The expansion is part of the company's "Fit for 2018" transformation and growth program.

Within the biopharmaceuticals division, the Bari site is part of Merck's fill & finish operations, along with facilities in Darmstadt and Aubonne (Switzerland). The drugs produced within this global network, particularly those used to treat infertility, are experiencing long-term growing demand. The new production facility in Bari will be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials, and ampoules.

Source: Merck KGaA

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here